INTRODUCTIONCardiovascular diseases are the second most common cause of death in Japan, and the number of new cases is continuously growing. Among the cardiovascular diseases, one‐third is attributed to ischemic heart diseases including acute myocardial infarction (AMI). For the better management and prognosis of AMI, prompt and accurate diagnosis is crucial.Cardiac troponin I is a protein that is specifically expressed in cardiomyocytes and is eluted in the blood when cardiomyocytes are injured such as by ischemia. Due to its specificity, cardiac troponin I has become one of the most reliable biomarkers for the diagnosis of AMI. In several guidelines including “Third Universal Definition of Myocardial Infarction ” and “2014 AHA/ACC Guideline for the Management of Patients With Non–ST‐elevation Acute Coronary Syndromes,” the 99th percentile cardiac troponin level in the normal population is accepted as the cut‐off for AMI. It is not clear, however, whether the cut‐offs determined in certain areas could be applied to racially and geographically different populations. One high‐sensitivity troponin I (hsTnI) assay (ARCHITECT STAT high‐sensitive troponin I, Abbott Laboratories, Chicago, IL, USA) is one of the most reliable troponin I assays on the Japanese market, which is reported to measure 80%‐90% of the general population. The
Journal of Clinical Laboratory Analysis – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud